0001193125-24-049205.txt : 20240228 0001193125-24-049205.hdr.sgml : 20240228 20240228073431 ACCESSION NUMBER: 0001193125-24-049205 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240228 ITEM INFORMATION: Other Events FILED AS OF DATE: 20240228 DATE AS OF CHANGE: 20240228 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Harpoon Therapeutics, Inc. CENTRAL INDEX KEY: 0001708493 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 473458693 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38800 FILM NUMBER: 24690188 BUSINESS ADDRESS: STREET 1: 611 GATEWAY BOULEVARD, SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 443-7400 MAIL ADDRESS: STREET 1: 611 GATEWAY BOULEVARD, SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 d744870d8k.htm 8-K 8-K
false 0001708493 0001708493 2024-02-28 2024-02-28

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 28, 2024

 

 

Harpoon Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-38800   47-3458693
(State or Other Jurisdiction
of Incorporation)		  

(Commission

File Number)

   (IRS Employer
Identification No.)

611 Gateway Boulevard, Suite 400

South San Francisco, California 94080

(Address of Principal Executive Offices, including Zip Code)

(650) 443-7400

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common stock, par value $0.0001 per share   HARP   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01.

Other Events.

As previously disclosed, on January 7, 2024, Harpoon Therapeutics, Inc., a Delaware corporation (“Harpoon”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Merck Sharp & Dohme LLC, a New Jersey limited liability company (“Merck”), and Hawaii Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Merck (“Merger Sub”), pursuant to which, and on the terms and subject to the conditions thereof, Merger Sub will merge with and into Harpoon (the “Merger”), with Harpoon surviving the Merger as a wholly-owned subsidiary of Merck. On February 8, 2024, Harpoon filed a definitive proxy statement (the “Definitive Proxy Statement”), as such may be supplemented from time to time, with the Securities and Exchange Commission (the “SEC”) in connection with, among other things, the Merger.

Certain Litigation

In connection with the Merger, one complaint has been filed against Harpoon and its directors in the United States District Court for the Northern District of California captioned Sapna Mistry v. Harpoon Therapeutics, Inc. et al., 3:24-cv-721 (filed February 7, 2024) and one complaint has been filed in the United States District Court for the District of Delaware captioned Matthew Wright v. Harpoon Therapeutics, Inc., et al., 1:24-cv-194 (filed February 13, 2024) (collectively, the “Complaints”). The Complaints generally allege that the Definitive Proxy Statement filed by Harpoon with the SEC misrepresents and/or omits certain purportedly material information relating to Harpoon’s financial projections, the analyses performed by the financial advisor to Harpoon’s Board of Directors in connection with the Merger, and potential conflicts of interest of Harpoon’s directors and officers. The Complaints assert violations of Section 14(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Rule 14a-9 promulgated thereunder against all defendants (Harpoon, its Board of Directors and certain officers) and violations of Section 20(a) of the Exchange Act against Harpoon’s directors and officers. The Complaints seek an order enjoining the proposed Merger, or in the event that the proposed Merger is consummated, an order rescinding the Merger or awarding rescissory damages, as well as costs, including attorneys’ and experts’ fees.

Harpoon has also received seventeen additional demands from February 2, 2024 to February 21, 2024 seeking additional disclosures in the Definitive Proxy Statement by purported Harpoon stockholders (the “Demands”).

Harpoon cannot predict the outcome of any litigation or the Demands. Harpoon and the individual defendants intend to vigorously defend against the Complaints, the Demands, and any subsequently filed similar actions. It is possible additional lawsuits may be filed or additional demand letters may be received arising out of the Merger between February 21, 2024 and consummation of the Merger. Absent new or significantly different allegations, Harpoon will not necessarily disclose such additional filings or demand letters.

Harpoon believes that the disclosures set forth in the Definitive Proxy Statement comply fully with all applicable laws, and denies the allegations in the Complaints described above. Nevertheless, in order to moot plaintiffs’ disclosure claims, avoid nuisance and possible expense and business delays, and provide additional information to its stockholders, Harpoon has determined voluntarily to supplement certain disclosures in the Definitive Proxy Statement with the supplemental disclosures set forth below (the “Supplemental Disclosures”). Nothing in the Supplemental Disclosures shall be deemed an admission of the legal merit of the Complaints or the Demands described above, or of the necessity or materiality under applicable laws of any of the disclosures set forth herein. To the contrary, Harpoon specifically denies all allegations in the Complaints and the Demands that any additional disclosure was or is required or is material.

SUPPLEMENTAL DISCLOSURES

The following supplemental disclosures should be read in conjunction with the Definitive Proxy Statement, which should be read in its entirety as supplemented. The inclusion in this supplement to the Definitive Proxy Statement of certain information should not be regarded as an indication that any of Harpoon or its directors, affiliates, officers, or other representatives, or any other recipient of this information, considered, or now considers, it to be material, and such information should not be relied upon as such. Defined terms used but not defined herein have the meanings set forth in the Definitive Proxy Statement. For clarity, new text within restated paragraphs from the Definitive Proxy Statement is highlighted with bold, underlined text, and deleted text within restated paragraphs from the Definitive Proxy Statement is highlighted with strikethrough text.

The disclosure under the heading “The Merger—Opinion of Centerview Partners LLC—Discounted Cash Flow Analysis” is hereby amended and supplemented by replacing the first full paragraph on page 51 of the Definitive Proxy Statement in its entirety with the following:

In performing this analysis, Centerview calculated a range of equity values for the Company Shares by (a) discounting to present value as of December 31, 2023 using discount rates ranging from 14.0% to 16.0% (based on Centerview’s analysis of Harpoon’s weighted average cost of capital), which was calculated using the Capital Asset Pricing Model and based on considerations that Centerview deemed relevant in its professional judgment and experience, taking into account certain metrics including target capital structure, levered and unlevered betas for a comparable group of companies, tax rates, market risk, and size premia) and using a mid-year convention: (i) the forecasted risk-adjusted, after-tax unlevered free cash flows of Harpoon over the period beginning on January 1, 2024 and ending on December 31, 2043, as set forth in the Projections, (ii) an implied terminal value of Harpoon, calculated by Centerview by assuming that (as directed by Harpoon management) Harpoon’s unlevered free cash flows would decline in perpetuity after December 31, 2043 at a rate of free cash flow decline of 40% year over year, and (iii) tax savings from usage of Harpoon’s federal net operating losses of $208 million as of December 31, 2022 and Harpoon’s estimated future losses, as set forth in the Internal Data, (b) adding to the foregoing results, Harpoon’s estimated cash of $110 million and subtracting an estimated $89 million payable to holders of Company Series A Preferred Stock upon redemption thereof, in each case as of December 31, 2023, as set forth in the Internal Data and (c) subtracting from the foregoing results the present value, as of December 31, 2023, of the impact of assumed equity raises of $100 million in 2024, $100 million in 2025 and $150 million in 2026, as set forth in the Internal Data.

The disclosure under the heading “The Merger—Opinion of Centerview Partners LLC—Other Factors” is hereby amended and supplemented by replacing the third full paragraph and sub-bullets on page 51 of the Definitive Proxy Statement in its entirety with the following:

Centerview noted for the Board certain additional factors solely for reference and informational purposes only, including, among other things, the following:

 

  •  

Historical Stock Trading Price Analysis. Centerview reviewed historical closing trading prices of the Company Shares during the 52-week period ended January 5, 2024 (the last trading day before the public announcement of the Merger), which reflected low and high stock closing prices for Harpoon during such period of approximately $3.29 to $13.70 per Company Share.

 

  •  

Analyst Price Target Analysis. Centerview reviewed stock price targets for the Company Shares in eight publicly available Wall Street research analyst reports as of January 5, 2024 (the last trading day before the public announcement of the Merger), which indicated low and high stock price targets for Harpoon ranging from $8.00 to $30.00 per Company Share and a median price target of $12.50 per Company Share.

 

  •  

Precedent Premiums Paid Analysis. Centerview performed an analysis of premiums paid in 31 selected transactions involving publicly traded biopharmaceutical companies with an offer value between $100 million and $1.0 billion for which premium data were available. The premiums in this analysis were calculated by comparing the per share acquisition price in each transaction to the closing price of the target company’s common stock for the date one day prior to the date on which the trading price of the target’s common stock was perceived to be affected by a potential transaction. Based on such analysis and other considerations that Centerview deemed relevant in its professional judgment, Centerview applied a range of 50% to 110% to Harpoon’s closing stock price on January 5, 2024 (the last trading day before the public announcement of the Merger) of $10.55, which resulted in an implied price range of approximately $15.85 to $22.15 per Company Common Share, rounded to the nearest $0.05.

 

The disclosure under the heading “The Merger—Certain Unaudited Prospective Financial Information” is hereby amended and supplemented by replacing the first full paragraph on page 55 of the Definitive Proxy Statement in its entirety with the following:

“At the direction of Harpoon’s management and the Board, Centerview calculated, solely based on the Projections, which were approved by the Board for reliance upon and use by Centerview in connection with the rendering of its opinion to the Board and in performing the related financial analyses as described in the section of this proxy statement captioned “—Opinion of Centerview Partners LLC,” and based on information and assumptions provided by Harpoon’s management, unlevered free cash flow as set forth below, which has been reviewed and approved by the Board for reliance upon and use by Centerview in connection with the rendering of its opinion to the Board and in performing the related financial analyses as described in the section of this proxy statement captioned “—Opinion of Centerview Partners LLC.” For purposes of calculating the discounted cash flow, Centerview calculated per Harpoon management the estimated (1) benefit from usage of net operating losses (“NOLs”) based on U.S. federal net operating losses of $208 million as of December 31, 2022 and estimated future losses and (2) impact of the cost of future potential capital raises of $100 million in 2024, $100 million in 2025, and $150 million in 2026. The estimated tax shield from NOLs was approximately $24 million in 2028, $32 million in 2029, $31 million in 2030, and $31 million in 2031. The values in the tables below do not take into account the effect of federal NOL usage and the cost of future capital raises.”

Additional Information and Where to Find it

In connection with the proposed transaction between Harpoon and Merck, Harpoon has filed with the SEC the Definitive Proxy Statement relating to a special meeting of its stockholders. Additionally, Harpoon may file other relevant materials with the SEC in connection with the proposed transaction. Investors and securityholders of Harpoon are urged to read the Definitive Proxy Statement and any other relevant materials filed or that will be filed with the SEC, as well as any amendments or supplements to these materials and documents incorporated by reference therein, carefully and in their entirety when they become available because they contain or will contain important information about the proposed transaction and related matters. The Definitive Proxy Statement has been mailed or otherwise made available to Harpoon’s securityholders. Investors and securityholders are able to obtain a copy of the Definitive Proxy Statement as well as other filings containing information about the proposed transaction that are filed by Harpoon or Merck with the SEC, free of charge on EDGAR at www.sec.gov, on the investor relations page of Harpoon’s website at ir.harpoontx.com/investors, by contacting Harpoon’s investor relations department at investors@harpoontx.com, or on Merck’s website at www.merck.com.

Participants in the Solicitation

Harpoon, Merck and certain of their directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Harpoon in respect of the proposed transaction and any other matters to be voted on at the special meeting of Harpoon stockholders scheduled for March 8, 2024. Information about Harpoon’s directors and executive officers, including a description of their interests, by security holdings or otherwise, in the proposed transaction are included in the Definitive Proxy Statement. Information about Merck and its directors and executive officers can be found in Merck’s proxy statement filed on April 3, 2023 and Merck’s other filings with the SEC available at the SEC’s Internet site (www.sec.gov), including any statements of beneficial ownership on Form 3 or Form 4 filed with the SEC after such proxy statement. Harpoon stockholders may obtain additional information regarding the participants in the solicitation of proxies in connection with the proposed transaction by reading the Definitive Proxy Statement and any other relevant documents that are filed or will be filed with the SEC relating to the proposed transaction. You may obtain free copies of these document using the sources indicated above.

 

Forward-Looking Statements

Any statements in this current report about Harpoon’s future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements about Merck’s proposed acquisition of Harpoon, the ability of Merck and Harpoon to complete the transactions contemplated by the Merger Agreement, including the parties’ ability to satisfy the conditions to the consummation of the Merger contemplated thereby and the other conditions set forth in the Merger Agreement, statements about the expected timetable for completing the transaction, Merck’s and Harpoon’s beliefs, expectations, and statements about the Complaints or the Demands, the projected impact of equity raises and projected NOL usage, and the benefits sought to be achieved in Merck’s proposed acquisition of Harpoon, the potential effects of the acquisition on Harpoon, the possibility of any termination of the Merger Agreement, as well as the expected benefits and success of Harpoon’s product candidates, and other statements containing the words “anticipates,” “believes,” “continue,” “expects,” “intends,” “look forward,” “plans,” “toward,” “will” and similar expressions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Harpoon’s control. These forward-looking statements are based upon Harpoon’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Such risks and uncertainties include, without limitation, (i) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; (ii) the satisfaction (or waiver) of closing conditions to the consummation of the proposed transaction, including the receipt of the requisite approval of Harpoon’s stockholders; (iii) the effects of disruption from the proposed transaction contemplated by the Merger Agreement and the impact of the announcement and pendency of the proposed transaction on Harpoon’s business; (iv) the effects of the proposed transaction on relationships with employees, other business partners or governmental entities; (v) the response of competitors to the proposed transaction; (vi) risks associated with the disruption of management’s attention from ongoing business operations due to the proposed transaction; (vii) the ability of the parties to consummate the proposed transaction in a timely manner or at all; (viii) significant costs associated with the proposed transaction; (ix) potential litigation relating to the proposed transaction; (x) restrictions during the pendency of the proposed transaction that may impact Harpoon’s ability to pursue certain business opportunities; (xi) risks related to the advancement of product candidates into, and successful completion of, preclinical studies and clinical trials; (xii) risks and uncertainties related to regulatory application, review and approval processes and Harpoon’s compliance with applicable legal and regulatory requirements; (xiii) general industry conditions and competition; (xiv) general economic factors; and (xv) risks associated with the Projections (including estimated impact of equity raises and estimated NOL usage) as described under the heading “Cautionary Note About the Projections” and under the heading “Cautionary Note Regarding Forward-Looking Statements” in the Definitive Proxy Statement. These risks, as well as other risks associated with the proposed transaction, are discussed in the Definitive Proxy Statement filed with the SEC in connection with the proposed transaction, and described in additional detail in Harpoon’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 and Harpoon’s other filings with the SEC, available on the SEC’s website at www.sec.gov. All forward-looking statements contained in this current report speak only as of the date hereof, and Harpoon specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      Harpoon Therapeutics, Inc.
Date: February 28, 2024     By:  

/s/ Julie Eastland

     

Julie Eastland

President and Chief Executive Officer

 EX-101.SCH 2 harp-20240228.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 harp-20240228_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 4 harp-20240228_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information
Feb. 28, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001708493
Document Type 8-K
Document Period End Date Feb. 28, 2024
Entity Registrant Name Harpoon Therapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-38800
Entity Tax Identification Number 47-3458693
Entity Address, Address Line One 611 Gateway Boulevard
Entity Address, Address Line Two Suite 400
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (650)
Local Phone Number 443-7400
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, par value $0.0001 per share
Trading Symbol HARP
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.harpoontx.com//20240228/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d744870d8k.htm harp-20240228.xsd harp-20240228_lab.xml harp-20240228_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d744870d8k.htm": { "nsprefix": "harp", "nsuri": "http://www.harpoontx.com/20240228", "dts": { "inline": { "local": [ "d744870d8k.htm" ] }, "schema": { "local": [ "harp-20240228.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "harp-20240228_lab.xml" ] }, "presentationLink": { "local": [ "harp-20240228_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.harpoontx.com//20240228/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-02-28_to_2024-02-28", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d744870d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-02-28_to_2024-02-28", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d744870d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.harpoontx.com//20240228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.harpoontx.com//20240228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.harpoontx.com//20240228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.harpoontx.com//20240228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.harpoontx.com//20240228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.harpoontx.com//20240228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.harpoontx.com//20240228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.harpoontx.com//20240228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.harpoontx.com//20240228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.harpoontx.com//20240228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.harpoontx.com//20240228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.harpoontx.com//20240228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.harpoontx.com//20240228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.harpoontx.com//20240228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.harpoontx.com//20240228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.harpoontx.com//20240228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.harpoontx.com//20240228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.harpoontx.com//20240228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.harpoontx.com//20240228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.harpoontx.com//20240228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.harpoontx.com//20240228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.harpoontx.com//20240228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.harpoontx.com//20240228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.harpoontx.com//20240228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001193125-24-049205-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-049205-xbrl.zip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end XML 15 d744870d8k_htm.xml IDEA: XBRL DOCUMENT 0001708493 2024-02-28 2024-02-28 false 0001708493 8-K 2024-02-28 Harpoon Therapeutics, Inc. DE 001-38800 47-3458693 611 Gateway Boulevard Suite 400 South San Francisco CA 94080 (650) 443-7400 false false false false Common stock, par value $0.0001 per share HARP NASDAQ true false